-

Daiichi Sankyo Confirms that a Texas Court has Entered Judgment on the Jury Verdict in Seagen Patent Dispute

  • No Enhancement of Damages Awarded by Court Despite Jury’s Finding of Willfulness

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) confirmed today that the U.S. District Court for the Eastern District of Texas has entered judgment on the April 8, 2022 jury verdict finding that ENHERTU® infringes Seagen’s U.S. Patent 10,808,039 (the ’039 patent), that the infringement was willful, and awarding Seagen $41.8 million in damages. Despite the jury’s finding of willfulness, the Court decided under the totality of the circumstances that enhancement (an increase) of damages was not warranted, and therefore did not enhance the damages award.

Daiichi Sankyo will continue to vigorously defend its rights and explore available post-trial motions and remedies to contest the judgment and damages awarded to Seagen.

The Court has not yet addressed whether to award a running royalty on future sales of ENHERTU® until the expiry of the ’039 patent in 2024. Any impact on Daiichi Sankyo’s consolidated financials for fiscal year ending March 31, 2023, is currently being evaluated and will be announced as soon as possible.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.

Contacts

U.S.
Kim Wix
Daiichi Sankyo, Inc.
kwix@dsi.com
+1 973-992-6633 (office)

Japan:
Masashi Kawase
Daiichi Sankyo Co., Ltd.
kawase.masashi.a2@daiichisankyo.co.jp
++81 3 6225 1126 (office)

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp

Daiichi Sankyo Co., Ltd.

TOKYO:4568

Release Versions

Contacts

U.S.
Kim Wix
Daiichi Sankyo, Inc.
kwix@dsi.com
+1 973-992-6633 (office)

Japan:
Masashi Kawase
Daiichi Sankyo Co., Ltd.
kawase.masashi.a2@daiichisankyo.co.jp
++81 3 6225 1126 (office)

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp

More News From Daiichi Sankyo Co., Ltd.

DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo

TOKYO--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1 trial evaluating DS1025 in adult patients with advanced or metastatic solid tumors with disease progression on or after at least one prior line of standard therapy. DS1025 is a specifically engineered, investigational, potential first-in-class CD25 directed antibody drug conjugate (ADC) containing an immuno-oncology optimized cytotoxic payload discovered by Daiichi Sankyo (TSE:4568). CD25 is a cell surface prot...

Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company’s oncology and specialty medicine business through a new globally integrated Commercialization Unit, effective April 1, 2027. As part of the operational excellence pillar outlined in the new Five-Year Business Plan of Daiichi Sankyo in May 2026, commercialization activities will be centralized and reo...

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026. “Daiichi Sankyo delivered strong revenue growth in the first quarter of fiscal year 2026 as we began execution of our new Five-Year Business Plan,” said Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo. “Three new U.S. approvals for Enhertu and Datroway were received in a single week in May, underscoring the continued strength of our portfolio where...
Back to Newsroom